ERBB2 and breast carcinoma: Concerning the clinical management of patients, the information from a drug bank should also be considered in the description of a phenotype, allowing a specification of how, for instance, HER2 positive breast cancer behaves in response to the 'Herceptin' (DB00072) treatment.